The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer

Post date May 15, 2022 — 08:35 Post Lock

Key Data Concepts:
? These are the company names, stock quotes, topics, and entities related to this data.

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Related Data

Bank of China Zhong Hong: Central Bank Digital Currency New Trends in Global Competition and Cooperation Bank Channel Hexun Network

May 20, 2022 — 17:00

Just now, the "cap removal market" was completely ignited! Soling shares have harvested 8 daily limits, and investors are hi: continue to increase positions! CFi.CN

May 20, 2022 — 16:50

Xin Pengjun: 5G calls for upgrading of classic business

May 20, 2022 — 16:03

Rongji Software won the bid for the upgrade and expansion project of the medical information (software) system of the Yangshan Branch of Xinyang Central Hospital

May 20, 2022 — 16:01

Evening Announcements May 17 These Announcements are worth watching

May 17, 2022 — 18:35

Kexing, Chengye Inactivation-Titanium Media Official Website

May 17, 2022 — 17:15

China Galaxy Securities: Pig prices are expected to continue to fluctuate and rise after the high level of pig companies in April.

May 17, 2022 — 16:10

China Galaxy maintains the recommendation rating of the agriculture, forestry, animal husbandry and fishery industry: the price of pigs sold by pig companies in April increased by nearly 10% month-on-month – yqqlm

May 17, 2022 — 15:43

A number of companies have clarified that "there is no fenugreek"! Beware of second-degree speculation in risk concept stocks_Sina Finance_Sina.com

May 17, 2022 — 15:02

Home » News » The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer